Barnabas, Robert Wood Johnson to merge

Barnabas Health and Robert Wood Johnson Health System have agreed to merge to create New Jersey’s largest healthcare system and one of the largest in the nation.

The new organization, RWJ Barnabas Health, is expected to be completed in 2016. RWJ Barnabas Health will annually represent operating revenues of more than $4.5 billion, 260,000 inpatient admissions, 2 million outpatient visits, nearly 700,000 emergency department visits, 23,000 births, nearly 30,000 employees, 9,000 physicians and 1,000 residents and interns. The new system will be comprised of 11 acute care hospitals, three children’s hospitals, a pediatric rehabilitation hospital, a behavioral health center, ambulatory care centers and five fitness and wellness centers.

“The new health system will comprise effectively every clinical service from primary to quaternary and greatly strengthen our commitment to medical education and research,” said Barry H. Ostrowsky, president and CEO of Barnabas Health. "The merger also will provide a large enough geography to be appropriate for the migration to population health management.”

“We are excited to move forward with this historic merger agreement which will offer the diverse communities in New Jersey expanded access to the best in academic medicine and community-based care,” said Stephen K. Jones, president and CEO of Robert Wood Johnson University Hospital and Robert Wood Johnson Health System.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.